Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL
February 4th 2023Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.
Watch
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL
January 29th 2023New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
Read More
PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant
January 28th 2023Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
Read More
Dr Adetunji Toriola Shares Breast Cancer Prevention Tactics for Premenopausal Women
January 10th 2023Adetunji T. Toriola, MD, PhD, professor of surgery at Washington University School of Medicine, explains how breast cancer prevention campaigns for premenopausal women have changed and how RANK ligand inhibition could influence screening accuracy.
Watch
Dr Mary Cushman: Disparities in Pulmonary Embolism Exist; We Need to Ask Why
December 14th 2022Health care providers must acknowledge unconscious bias and watch for it to make sure treatments are given equitably, said Mary Cushman, MD, professor of medicine at the University of Vermont, director of the thrombosis and hemostasis program at the University of Vermont Medical Center.
Read More
TRANSFORM Data Support Liso-cel as Second-line Treatment for LBCL, Says Dr Jeremy Abramson
December 13th 2022The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.
Watch
Dr Ajai Chari Talks Phase 1 Results of Bispecific Antibody Talquetamab for Multiple Myeloma
December 13th 2022Ajai Chari, MD, professor of medicine, director of clinical research, Icahn School of Medicine at Mount Sinai, explains the mechanism of action of talquetamab and what method of delivery patients may prefer.
Watch
Dr Elias Jabbour: Third-line Ponatinib “Optimal” for Patients With CML-CP Without T3151 Mutation
December 12th 2022Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.
Watch
Breakthrough COVID-19 Infection in 10% of Patients With Blood Cancer, LLS Data Show
December 12th 2022About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.
Watch
FDA Leader at ASH: Decentralized Clinical Trials Aren’t “All or Nothing”
December 12th 2022Nicole Gormley, MD, acting director of the Division of Hematology Products at FDA, explained that the agency wants to maintain momentum gained during the pandemic that moved clinical trials beyond the walls of academic centers.
Read More
After a Week, Efgartigimod Lets 38% of Patients With ITP Reach Platelet Counts to Avoid Bleeding
December 11th 2022Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden bleeding events.
Read More
I-SPY2 Supports Neoadjuvant Cemiplimab/REGN3767 in Early-Stage, High-Risk Breast Cancer
December 10th 2022The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant therapy for early-stage, high-risk breast cancer, and new data were presented yesterday at the San Antonio Breast Cancer Symposium.
Read More
10-Year Babytam Data Show Reduced-Dose Tamoxifen Still Producing Positive Results
December 9th 2022Babytam is the 5-mg daily dose of tamoxifen being studied in the ongoing TAM-01 study, which is investigating incidence of invasive breast cancer or ductal carcinoma in situ among high-risk women who have received the treatment regimen for 3 years.
Read More
Dr Lola Fayanju Shares How Providers Can Leverage PROs to Improve Breast Cancer Care
December 9th 2022Patient-reported outcomes (PROs) within breast cancer settings can be instrumental in helping patients feel heard and improving their overall quality of care, said Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS, chief of breast surgery at Penn Medicine.
Watch